Delivered-To: pgepnewsletter@gmail.com
Received: by 2002:a98:c004:0:b0:1eb:e128:bbe3 with SMTP id l4csp3962312eic;
        Mon, 15 Jan 2024 14:29:13 -0800 (PST)
X-Google-Smtp-Source: AGHT+IGhrTxnh9GukEWBBm0HhIoOGzLDchHkjQjy2fP8aIrO1XSnwgMUZFoQKSBlOQe9AldEHLlJ
X-Received: by 2002:ac8:7d4c:0:b0:42a:3fe:b764 with SMTP id h12-20020ac87d4c000000b0042a03feb764mr17660qtb.33.1705357752718;
        Mon, 15 Jan 2024 14:29:12 -0800 (PST)
ARC-Seal: i=1; a=rsa-sha256; t=1705357752; cv=none;
        d=google.com; s=arc-20160816;
        b=jf4y0MWZly4QVUqtKK/A0udz83CBuTnJN1N3REPOIjP7UV17eW1vFtCjJc3LYDfQyR
         SVPqixp5X0QKD5ORwifYuPmw8+EB9JphUFabU3t8YNmeKIIJHMzA042XU7FwpQcfrrmE
         //NJkmvZJk9LhGTQPg7I9gIuGoQMX12aVmNWprHL0tuin46HgfTzINmHjmoKuo8bNlP6
         SQlqAmxTKbEMEZZ7kgZehaVNMv/VTRp24E+SL8IpDDEhAgxU1ffawsS68n0SNA+N2DXC
         kRsltkfmcY7TnJlpFpJWpZPPxl5hylNPLXBf0yjvJtpjfCA7BwhYZwRrA3/Lw3ITymQw
         UItQ==
ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20160816;
        h=list-unsubscribe:to:reply-to:subject:message-id:mime-version:from
         :date:dkim-signature:dkim-signature;
        bh=iAXlHmuiDIv2/lINH+dYVo7LaVEc/0a33adnjVKvdcg=;
        fh=m8+yFGL9AGrkSifADXzxzWHypeMVd9MF7/kbikeN2H4=;
        b=0rk8YGCMJuY2nFAOfe6srG4+xhnarZvtd3Jem8DysEqQybd4ZpyB+3En/luGePDAhi
         lbF0Z9LAyHQaabShYJ/fZjJWGmVvROKZfxfnYIyVvor8mItB20dItUoWU5ZFxSw96x2P
         V+g+HTRpG6qI649fH9gp3vNcMDXFKRIZ8U2YO/Zzy1zzujc97itcoWyYN6c4eijkgdSQ
         UbcnAvwTLOGhWgrZrhGRii5HaS0w2XFGQJO5JwhTZcCv7OS9Bvrs8Z5Jvf5xfiizFyJ9
         mDm4juOyW8jzeeAdi7zJX3HZgYmw5zYatcBsyiZMjCiHhm5Yp7uELHwyQFJea7jS47sC
         zmTw==
ARC-Authentication-Results: i=1; mx.google.com;
       dkim=pass header.i=@isid.org header.s=s1 header.b=HGWl3iC6;
       dkim=pass header.i=@sendgrid.info header.s=smtpapi header.b=PQ056efY;
       spf=pass (google.com: domain of bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org designates 167.89.81.226 as permitted sender) smtp.mailfrom="bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org";
       dmarc=pass (p=NONE sp=NONE dis=NONE) header.from=isid.org
Return-Path: <bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org>
Received: from xtrwrkzn.outbound-mail.sendgrid.net (xtrwrkzn.outbound-mail.sendgrid.net. [167.89.81.226])
        by mx.google.com with ESMTPS id br22-20020a05622a1e1600b00429735c0f78si8618034qtb.807.2024.01.15.14.29.12
        for <pgepnewsletter@gmail.com>
        (version=TLS1_3 cipher=TLS_AES_128_GCM_SHA256 bits=128/128);
        Mon, 15 Jan 2024 14:29:12 -0800 (PST)
Received-SPF: pass (google.com: domain of bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org designates 167.89.81.226 as permitted sender) client-ip=167.89.81.226;
Authentication-Results: mx.google.com;
       dkim=pass header.i=@isid.org header.s=s1 header.b=HGWl3iC6;
       dkim=pass header.i=@sendgrid.info header.s=smtpapi header.b=PQ056efY;
       spf=pass (google.com: domain of bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org designates 167.89.81.226 as permitted sender) smtp.mailfrom="bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org";
       dmarc=pass (p=NONE sp=NONE dis=NONE) header.from=isid.org
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=isid.org;
	h=content-type:from:mime-version:subject:reply-to:x-feedback-id:to:
	list-unsubscribe:cc:content-type:from:subject:to;
	s=s1; bh=iAXlHmuiDIv2/lINH+dYVo7LaVEc/0a33adnjVKvdcg=;
	b=HGWl3iC64VFBbCpPzcXTtoTOcn1uANy7stLpIDCzheq51CxYEANK1PCjbWdKXI4q2+wT
	J8SQ8vwMU8lfz777wVw7Wair6kE17WECbrNL41dTtnhGc/Ti0gIdHl6JVovs5CK/EO8Zlp
	JiGq9bJcFUIEn/ZbBjE9ZKS7XjIMq6+/tgEBrFMFf+DX9j6sveNzYuCo83JTqZt/p5AAlI
	T0+x4SX47RMgByuFmJz5gdzyvE7BAwWpbwHIJba+h9lO4LS0ka09oyNUlnHi5hOj8tfEnt
	bhbjdX6d5ybdQWiVc75brUnX6PfbQXoAXdEL+pqM5MiXV+yL1cPOF/r8O+33TdSA==
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=sendgrid.info;
	h=content-type:from:mime-version:subject:reply-to:x-feedback-id:to:
	list-unsubscribe:cc:content-type:from:subject:to;
	s=smtpapi; bh=iAXlHmuiDIv2/lINH+dYVo7LaVEc/0a33adnjVKvdcg=;
	b=PQ056efYQPKJBo4heNVKVNJuOf/8023bQR0MH9Hiid5u4QHFFYH0c5KVyr2jbMzRpf3Y
	zknvygf4raT6PpCqF/UNWYm6m3YKS2pNui8bJUE7VJnadkLafj4xck9Te2Uw2bVNr2wkj9
	U/z1KbZV1+zZSLso0XEXAo5kjWVeYWRfk=
Received: by filterdrecv-66b6fdb7fb-2vxdq with SMTP id filterdrecv-66b6fdb7fb-2vxdq-1-65A5B1B7-41
        2024-01-15 22:29:12.002558489 +0000 UTC m=+7789641.340968251
Received: from MTkyNjg2NjI (unknown)
	by geopod-ismtpd-19 (SG) with HTTP
	id OGOe-wIFT4CT3zh9r4iiiA
	Mon, 15 Jan 2024 22:29:11.948 +0000 (UTC)
Content-Type: multipart/alternative; boundary=bb19a8ce0bf4d619f3ed13044c590a3c627cf12d6dde3a63b18fde0a7a3a
Date: Mon, 15 Jan 2024 22:29:12 +0000 (UTC)
From: ProMED <promed@isid.org>
Mime-Version: 1.0
Message-ID: <OGOe-wIFT4CT3zh9r4iiiA@geopod-ismtpd-19>
Subject: PRO/AH/EDR> Lassa fever - West Africa (02): Nigeria, update
Reply-To: noreply@isid.org
X-Feedback-ID: 19268662:SG
X-SG-EID: 
 =?us-ascii?Q?lYKUi1ucKQwcfoVB1xAcbBSlsJP9QSi7ed2VWI0p5NjpCc5BQK+kujBGGO1mU1?=
 =?us-ascii?Q?iBsM=2FioW+QLl6S+O1Y0e+AJZYfQHiIa3AshLMfR?=
 =?us-ascii?Q?YuAGCeRPxAVnIfm3uVMILTGx84qRhkJ7nod8kK1?=
 =?us-ascii?Q?X8e2c7mr6uDAicQyEotakG+q42DKA6i=2FrQVeN7M?=
 =?us-ascii?Q?viX7K35bHNu6vtN3eMdyc2oOHeAyMIJcFCle91=2F?=
 =?us-ascii?Q?3Rix=2FBEdDaj8bw77GWh04PHpEpnNap9BWJA8Tq?=
X-SG-ID: 
 =?us-ascii?Q?se=2F49CGmbS0sfR97ImeXvNhg9p9jggtUUChgqoY2wUiShGf=2FO8XJWpH34Od4Nd?=
 =?us-ascii?Q?fxXa6jil96uRcJkF+N+LeVnO1tx80ddOyoyOo=2Fc?=
 =?us-ascii?Q?Brxcl3ERAm0cOY743=2FFH59DWiSf5OzXORh1DLKt?=
 =?us-ascii?Q?hb1NMKty3PsA5ju0ZzxCrq1WQuZSEQf=2FJlWtgqv?=
 =?us-ascii?Q?cZmsyCHlNUZsDlZUoZQOau2bdwbjsRASviGGUkd?=
 =?us-ascii?Q?jUgJnKe6r9GrUx0JNtfTYJ3xAK8Q2rKulWSHza1?=
 =?us-ascii?Q?4VLbEXoh5+gZmbqJ2Ii8Af1DzBGbAj3lTGISs=2FF?=
 =?us-ascii?Q?Rfmd09LrtTkoZVwhcGQ7+dtzVgVn7hDYQSEkRuj?=
 =?us-ascii?Q?U7NlXfVyqOqrm9cL3iOvkkuCU9YlRK5sYbWz+am?=
 =?us-ascii?Q?838URfMxd9J1VG7VsD2tO5W7fdJxzBCJOXahCoI?=
 =?us-ascii?Q?kauRz+rnqyR3a1Um5bxO=2FsUEFlpw0+Mzt0Uxfxh?=
 =?us-ascii?Q?2BSFIuc4RY0gZaCmPgt+UcMf2O7u9=2FB2G5RzlLs?=
 =?us-ascii?Q?tYqbuLscAafMrt1lr9KV9UIdKfzC8TESRAeb6ri?=
 =?us-ascii?Q?KWGvy0zRPWBflsiWCTagAUSXqbRLD54XjV9ROVi?=
 =?us-ascii?Q?F0HZEci6xz=2F=2FF=2FsKq2qn4eQ6cJWsSFKvW8R+Cdd?=
 =?us-ascii?Q?n8DO0MjPgZFxsryTJMadMtiWoOhnbaWm5dlwzVS?=
 =?us-ascii?Q?MGinNnVqZqKCafvxO25vzYULvIgZIsnw0kyCfJk?=
 =?us-ascii?Q?lLgV3T9E3BizVkHuLLkxujEI54U2xTdvzvHo9Wh?=
 =?us-ascii?Q?iFHpSBfgzd0J45faQcxNnCNvcPmS58Wwu2EJHyy?=
 =?us-ascii?Q?ySYHGIrvgibI9upzzjEzZ4d5BQ=3D=3D?=
To: pgepnewsletter@gmail.com
X-Entity-ID: 3CKJgmVGbBVD214dsRqreg==
List-Unsubscribe: 
 =?us-ascii?Q?=3Cmailto=3Aunsubscribe=40em7004=2Eisid=2Eorg=3Fsubject=3D19268662=2E9-3ZUPWuV?=
 =?us-ascii?Q?GN8GJHziHnKkd6Ht9wwdzJmBe5kWkLWUaRoMDAw?=
 =?us-ascii?Q?dTAwMCrE7SXGSi-cAxyntjGkAB70e-oHs1TtmDw?=
 =?us-ascii?Q?UXLk-zJW8EROTfwrnBRnjaZpiRTBPcl-Xc24qq5?=
 =?us-ascii?Q?H8e8eTO8m788Dwnu0nHRWO=5FHMuGxa8vWImEHO82?=
 =?us-ascii?Q?5gkk8ayAXcn=5FCw5Tg=3D=3D=2EzhkPk9EKu6riwDvbE2L?=
 =?us-ascii?Q?cjRvHFiRiQetZQjECjMEALTFoMDAwdTAwMEiBcJ?=
 =?us-ascii?Q?eFWhBzBBoKDhyd3ZCE7AlsDSOhFy7PxBAla0YKC?=
 =?us-ascii?Q?ALtBBkeC4-7AB5lAu=5FqVGsdk8PuEtf6uLYUhB1P?=
 =?us-ascii?Q?OskRobKwGY6ykfjVWKyiH2UGghhN2bLI4UgazGf?=
 =?us-ascii?Q?q9f1pFS8C0ckzXqNEKs=5FnQqWps13m7kHSvHOntH?=
 =?us-ascii?Q?bOPo6w7l8J-NO1dhoiv3qnrzuod56eiL5AT1=5FL7?=
 =?us-ascii?Q?6Lnqt3uz0P5Lic-itqUpgVCEQQ52EgOozKz27GF?=
 =?us-ascii?Q?IGKf9IUtoyK0kZbkLoa3-jnHE=5FAazJ2Tc7QGnM-?=
 =?us-ascii?Q?uN8RSk1vRSzZS6n9qcB0V9=5FE4rJ03r8FpYqf5Tx?=
 =?us-ascii?Q?xk=5F8-5AJaybxKA=5FOCV=5Fp3QTvQFkcJQ26FW0OASP?=
 =?us-ascii?Q?wnjwtMOlV582tXBjYLTnAk=5Fu3Ly6wvHX5vVs4iL?=
 =?us-ascii?Q?qmTAZ9HbKQCo6ESyFeUPERk2GVHb0SctJ0atMug?=
 =?us-ascii?Q?Y5Pt0TBPcUEy5T=5FMflLk3moPPnQZI4HH8VINQri?=
 =?us-ascii?Q?JRaxvrIHAv=5FManFwm95F0wmw=5FWrr4Ok9U5mwQtj?=
 =?us-ascii?Q?6w4YwUQRnHYp7yLKVRydbnRzaCq1Bn06barrkvP?=
 =?us-ascii?Q?vUzecbNxXjmbMDtS20CnGV3s8vow3sPt5CssG-=5F?=
 =?us-ascii?Q?ZqcKS=5FsAWNUx90c9CaH1df7fV-GURTZXuQIg1PV?=
 =?us-ascii?Q?49wZhj8H58Zs0ImG54kEZ0e73FGuyp-W8z2bhy8?=
 =?us-ascii?Q?zdU9t6l35Vcuz3j9tu0DZBdTQO3hjuGRNdHAM8g?=
 =?us-ascii?Q?Y3rMO4eRdZt7juvCw3ABGDuxqzOE=5FcB2oXHiZnQ?=
 =?us-ascii?Q?oznoL3E6DTC4VodP-RvgcN0U9xkVwww9=5Fm85P44?=
 =?us-ascii?Q?F9osuuYtyD2xw2v=5FKWt9=5FyMTn6nW=5FFHkMIfoQmZ?=
 =?us-ascii?Q?IWJZfYiLZm1sd5NKMRoJQ96lTdp62Y=5FnH-370=5Fn?=
 =?us-ascii?Q?4XW0QDScz0Eko0-FQb1Q0m2qdUHjepRevapcJn4?=
 =?us-ascii?Q?gaQcQex947ji5V1MPv---Q12-SWpl4kHu0Jl5lX?=
 =?us-ascii?Q?xQgHguM=5F-Ri35a93yI=5F3dgtXYSaP5tDHqUQsUXG?=
 =?us-ascii?Q?E5GFculzo0YUmZ6Vr2krmz0bz9kCn3-eD9-tSMp?=
 =?us-ascii?Q?0z8HZA=3D=3D=3E?=

--bb19a8ce0bf4d619f3ed13044c590a3c627cf12d6dde3a63b18fde0a7a3a
Content-Transfer-Encoding: quoted-printable
Content-Type: text/plain; charset=us-ascii
Mime-Version: 1.0

LASSA FEVER - WEST AFRICA (02): NIGERIA, UPDATE
***********************************************
A ProMED-mail post
<http://www.promedmail.org>
ProMED-mail is a program of the
International Society for Infectious Diseases
<http://www.isid.org>

Date: Mon 8 Jan 2024
Source: Premium Times [edited]
<https://www.premiumtimesng.com/news/top-news/657102-lassa-fever-nigeria-re=
cords-over-1000-infections-219-deaths-in-2023.html>


The Nigerian government has said the country recorded 1227 confirmed
cases and 219 deaths of Lassa fever across 28 states from week 1 to 51
of 2023.

The data is contained in the latest report by the Nigerian Centre for
Disease Control (NCDC).

The situation report published on the website of NCDC shows an
increase in confirmed cases and fatalities recorded in 2023 when
compared to 1055 cases and 189 deaths recorded within the same period
in 2022.

Cumulatively from week 1 to week 51, 2023, the report noted that 216
deaths were reported with a case-fatality rate (CFR) of 17.5%, which
is lower than the CFR for the same period in 2022 (17.9%).

According to the report, the number of new confirmed Lassa fever cases
in week 51 spanning 18 to 24 Dec 2023 increased from 10 in the
previous week to 26 cases.

The report also noted that the number of suspected cases in 2023
(8978) increased compared to 2022 (8130), adding that 2 health workers
were affected in week 51.

More details
------------
In total for 2023, NCDC noted that 28 states recorded at least one
confirmed case across 121 local government areas.

Of all confirmed Lassa fever cases. 77% were reported from Ondo, Edo,
and Bauchi states. While Ondo state accounted for 35%, Edo and Bauchi
recorded 28 and 14%, respectively.

According to the report, the most affected age group was 21-30 years,
with cases ranging from 1 to 93 years, and the median age of confirmed
cases was 32 years.

In response to the situation, NCDC said the multi-sectoral public
health emergency operation centres (PHEOC) have been activated at both
the national level and in the affected states.

Challenges
----------
Meanwhile, NCDC also highlighted the challenges in combating Lassa
fever cases in Nigeria, which include the late presentation of cases
resulting in an elevated case fatality rate.

Others are poor health-seeking behaviour due to the high cost of
treatment and clinical management of Lassa fever; poor environmental
sanitation conditions observed in high-burden communities; and poor
awareness observed in those high-burden communities.

Additionally, challenges like poor environmental sanitation conditions
and low awareness were also observed in high-burden communities.

Lassa fever
-----------
Lassa fever is an acute viral hemorrhagic (excessive bleeding) illness
that is transmitted to humans through contact with food or household
items contaminated by infected rodents or contaminated persons.

Its symptoms include fever, headache, sore throat, general body
weakness, cough, nausea, vomiting, diarrhoea, muscle pains, chest
pain, and, in severe cases, unexplainable bleeding from ears, eyes,
nose, mouth, and other body openings.

[Byline: Mariam Ileyemi]

--
Communicated by:
ProMED
via
ProMED-EAFR

[For 2023, the epicenter of the Lassa fever outbreak in Nigeria was
Ondo state. Late presentation of cases was one of the major challenges
faced in 2023. This is not surprising, as about 80% of cases present
with non-specific symptoms common to other major causes of febrile
illnesses in the region such as malaria and typhoid fever. About 20%
of cases present with severe manifestations including bleeding and
shock. A high index of suspicion leads to early diagnosis and
treatment with the antiviral ribavirin, which is effective in the 1st
few days of developing symptoms of infection. - Mod.AA

ProMED map of Nigeria:
<https://promedmail.org/promed-post?place=3D8714223,62>]

[See Also:
Lassa fever - West Africa (01): Nigeria (BE) fatal
http://promedmail.org/post/20240106.8714080
2023
----
Lassa fever - West Africa (14): Nigeria (BE)
http://promedmail.org/post/20231231.8713999
Lassa fever - West Africa (13): Nigeria
http://promedmail.org/post/20231227.8713928
Lassa fever - West Africa (12): Nigeria
http://promedmail.org/post/20231011.8712574
Lassa fever - West Africa (08): Nigeria
http://promedmail.org/post/20230408.8709407
Lassa fever - West Africa (07): Nigeria
http://promedmail.org/post/20230308.8708805
Lassa fever - West Africa (03): Nigeria
http://promedmail.org/post/20230213.8708341
Lassa fever - West Africa (02): Nigeria
http://promedmail.org/post/20230124.8707942
Lassa fever - West Africa: Nigeria, 2022
http://promedmail.org/post/20230111.8707735]
.................................................aa/may/ya/tw/jh
*##########################################################*
************************************************************
ProMED makes every effort to verify the reports that are posted, but the ac=
curacy
and completeness of the information, and of any statements or opinions base=
d
thereon, are not guaranteed. The reader assumes all risks in using informat=
ion
posted or archived by ProMED. ISID and its associated service providers sha=
ll not
be held responsible for errors or omissions or held liable for any damages =
incurred
as a result of use or reliance upon posted or archived material.
************************************************************
Donate to ProMED. Details available at: https://isid.networkforgood.com/pro=
jects/79924-invest-in-the-mission.
************************************************************
Visit ProMED's website at https://www.promedmail.org/.
Submit all items for posting via the ProMED website at https://promedmail.o=
rg/submitinfo/.
If you have any questions or need support, please contact us via the ProMED=
 website at  https://promedmail.org/support/.
You may subscribe/unsubscribe at  https://isid.org/promedmail-subscribe/.
Unsubscribe Preferences ( https://u19268662.ct.sendgrid.net/asm/?user_id=3D=
19268662&data=3DB60eYZtS9W6UIF-Dni9pGXN7hExwAH7GiSEiYlmiDh9oMDAwdTAwMJvVvij=
U-KxiToeug_yXhKXJmGJX47P0_naIkMj0HrNzZWPa1hFC5KK8K3GWPYCk3XptNvAgLESLlakTNp=
wj-gwA759OSxsN0ZuA6iCxFLMfKrJrw7SccAd0yS5yrofhXjbdExeKv2siyy90BIeduugG9R7Lh=
aWyBYg5wVbnDSQxfcaM1XRvwPM4IWhDRuBkJVd81AAfbK4j-W5BAs7oZzwyuCGH2CpFZL7R7SUe=
iPJwS8xc81r_7cEYKEtkNuyw-xpyJJV-LYP14XSl4zFvNXczy8f1jneulVXlrYuPA8YYBuWDlne=
wrqPBVkqwS6RmEaJUtmpZGmPZygdFxrVZJgglhdDWfepUeOT-f1AnyTs2MA7_2TabZEiPGxR8Ig=
0g_NPFvckDqdi7L-lY0mc7yhhHhQ3cYSqB890GSI2Y2yyaksA_55D6yhS5ypwvLd4KANj7ds-2l=
ESWNBpvySZTqam7I25BHb0-K3E-o-tiB-zzeXiqAP-zC5-M3Iyx4zxqp7WqgggbewAdA09U3__O=
aV1at_2ydTHpCXH_pygwUaRNhuV_2S9aGtf3XJkmbs-GhnjQFPhvxafddaHgGVdToj9Vo7-CFF5=
ZnSEIBNUX0Vr2IOCvtgjp0iOl2BuZNYFOH0ax_ioXmUlOyDmDJKtzL5x1FTEmHA8G1pNpReV3p9=
khqTGCMs91Rs33Z7akZN78S6RRaZ9ak8qus4uiwrKEreU4MgsLhcb845kMGTKzOXXsBa1nnM3Ik=
zs-EKt2cU5jQqLM91BpPwRmu4gY8l9deOxgoU_Uj1HBBfgDoRmyaBB6Flba8Yl25piSVKTtl72d=
vpmIMMurLHsvUJg_fyWiL6BFQVqO7OFoxSs-No3oi1rQjBuBL3-lMG37bwOm-fTeFk_uS0hjt9w=
NgqBWGf2LVQgd2vPuMe6X7wGpwTfGROBXXou-THcK4XBPonH5jV1Irw0GYzoXqH7oa1xzs45UNs=
Ebu2_S1WwU2LYpXwzWNGXw6d624tjXL-sMaP_M8m_iDbW-Mha5BQ-MgJq5-FuWgvr8wafFsUz9C=
bXjIgy3HVCvYJmOKUmu3PmHt_nLQM_HbzuCw84VOLK01cAu382YwxgX2rBmc_gg-d96MA1nHX5A=
RhsxHpQ0GcSpEmXRW5A4t0FWx4SMJ-CsseY2zbWgQZarm_aMikMZTOV5zqjws74e )
############################################################
############################################################

--bb19a8ce0bf4d619f3ed13044c590a3c627cf12d6dde3a63b18fde0a7a3a
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset=us-ascii
Mime-Version: 1.0

<!DOCTYPE HTML>
<html>
<head>
<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3DUTF-8" />
</head>
<body>LASSA FEVER - WEST AFRICA (02): NIGERIA, UPDATE<br>******************=
*****************************<br>A ProMED-mail post<br><a href=3D"https://u=
19268662.ct.sendgrid.net/ss/c/wscE2ng5fl6JrPIt48tisIijpefK5PNjW-mL-YZGnfgDO=
xU1G3gjwnPSi2Tfv3HA/430/Ngr20MNiSA2bTgypXA8XQA/h0/2O7OFJm7L80fJerHmaI0VJf3y=
AFV4KiK-sjbtMrEqyY">http://www.promedmail.org</a><br>ProMED-mail is a progr=
am of the<br>International Society for Infectious Diseases<br><a href=3D"ht=
tps://u19268662.ct.sendgrid.net/ss/c/wscE2ng5fl6JrPIt48tisCT5tpD4Upm3qyMCbc=
YSQvc/430/Ngr20MNiSA2bTgypXA8XQA/h1/bb0fcmxV0m8FM3QAZv7JNu-5bA6U_YEU-tf21lt=
xMAg">http://www.isid.org</a><br><br>Date: Mon 8 Jan 2024=0D<br>Source: Pre=
mium Times [edited]=0D<br><a href=3D"https://u19268662.ct.sendgrid.net/ss/c=
/TLh_csrC34X_iXpbYoMam-Meyahe3DlkX6dr-o43m-oBOQ83rZmFR5FUSW5cfb6Xs8maXwjX6D=
RzkjWHeoGfIsCdJ1-OFB1gve7hSfD2JSqMy7jL7c_Om2anyopQSwmakv7fnvazNVCPpPljriUWS=
gaIbnBudk6zJWDBpu9X9RpqwS4GOG898jtvSsyOz7zY/430/Ngr20MNiSA2bTgypXA8XQA/h2/d=
-RwJPI_QJJc5U-QL-u44H54SkY2NqO0wluOe3asXHg">https://www.premiumtimesng.com/=
news/top-news/657102-lassa-fever-nigeria-records-over-1000-infections-219-d=
eaths-in-2023.html</a>=0D<br>=0D<br>=0D<br>The Nigerian government has said=
 the country recorded 1227 confirmed<br>cases and 219 deaths of Lassa fever=
 across 28 states from week 1 to 51<br>of 2023.=0D<br>=0D<br>The data is co=
ntained in the latest report by the Nigerian Centre for<br>Disease Control =
(NCDC).=0D<br>=0D<br>The situation report published on the website of NCDC =
shows an<br>increase in confirmed cases and fatalities recorded in 2023 whe=
n<br>compared to 1055 cases and 189 deaths recorded within the same period<=
br>in 2022.=0D<br>=0D<br>Cumulatively from week 1 to week 51, 2023, the rep=
ort noted that 216<br>deaths were reported with a case-fatality rate (CFR) =
of 17.5%, which<br>is lower than the CFR for the same period in 2022 (17.9%=
).=0D<br>=0D<br>According to the report, the number of new confirmed Lassa =
fever cases<br>in week 51 spanning 18 to 24 Dec 2023 increased from 10 in t=
he<br>previous week to 26 cases.=0D<br>=0D<br>The report also noted that th=
e number of suspected cases in 2023<br>(8978) increased compared to 2022 (8=
130), adding that 2 health workers<br>were affected in week 51.=0D<br>=0D<b=
r>More details=0D<br>------------=0D<br>In total for 2023, NCDC noted that =
28 states recorded at least one<br>confirmed case across 121 local governme=
nt areas.=0D<br>=0D<br>Of all confirmed Lassa fever cases. 77% were reporte=
d from Ondo, Edo,<br>and Bauchi states. While Ondo state accounted for 35%,=
 Edo and Bauchi<br>recorded 28 and 14%, respectively.=0D<br>=0D<br>Accordin=
g to the report, the most affected age group was 21-30 years,<br>with cases=
 ranging from 1 to 93 years, and the median age of confirmed<br>cases was 3=
2 years.=0D<br>=0D<br>In response to the situation, NCDC said the multi-sec=
toral public<br>health emergency operation centres (PHEOC) have been activa=
ted at both<br>the national level and in the affected states.=0D<br>=0D<br>=
Challenges=0D<br>----------=0D<br>Meanwhile, NCDC also highlighted the chal=
lenges in combating Lassa<br>fever cases in Nigeria, which include the late=
 presentation of cases<br>resulting in an elevated case fatality rate.=0D<b=
r>=0D<br>Others are poor health-seeking behaviour due to the high cost of<b=
r>treatment and clinical management of Lassa fever; poor environmental<br>s=
anitation conditions observed in high-burden communities; and poor<br>aware=
ness observed in those high-burden communities.=0D<br>=0D<br>Additionally, =
challenges like poor environmental sanitation conditions<br>and low awarene=
ss were also observed in high-burden communities.=0D<br>=0D<br>Lassa fever=0D=
<br>-----------=0D<br>Lassa fever is an acute viral hemorrhagic (excessive =
bleeding) illness<br>that is transmitted to humans through contact with foo=
d or household<br>items contaminated by infected rodents or contaminated pe=
rsons.=0D<br>=0D<br>Its symptoms include fever, headache, sore throat, gene=
ral body<br>weakness, cough, nausea, vomiting, diarrhoea, muscle pains, che=
st<br>pain, and, in severe cases, unexplainable bleeding from ears, eyes,<b=
r>nose, mouth, and other body openings.=0D<br>=0D<br>[Byline: Mariam Ileyem=
i]=0D<br>=0D<br>--=0D<br>Communicated by:=0D<br>ProMED=0D<br>via=0D<br>ProM=
ED-EAFR<br><br>[For 2023, the epicenter of the Lassa fever outbreak in Nige=
ria was<br>Ondo state. Late presentation of cases was one of the major chal=
lenges<br>faced in 2023. This is not surprising, as about 80% of cases pres=
ent<br>with non-specific symptoms common to other major causes of febrile<b=
r>illnesses in the region such as malaria and typhoid fever. About 20%<br>o=
f cases present with severe manifestations including bleeding and<br>shock.=
 A high index of suspicion leads to early diagnosis and<br>treatment with t=
he antiviral ribavirin, which is effective in the 1st<br>few days of develo=
ping symptoms of infection. - Mod.AA=0D<br>=0D<br>ProMED map of Nigeria:<br=
><a href=3D"https://u19268662.ct.sendgrid.net/ss/c/sSnCkKCWBvais3EuVAOvgy2W=
OIX7pp1nXnn4AbwuQ3Z6WbkfhqXYXU-aTMPJ8yThm8QNL7qM_rlAQcM698QQHQ/430/Ngr20MNi=
SA2bTgypXA8XQA/h3/PnnG-ONQXfCuNq3D8oiA6vYoKTwgGMGuHPX2cN5wdXA">https://prom=
edmail.org/promed-post?place=3D8714223,62</a>]<br><br>[See Also:<br>Lassa f=
ever - West Africa (01): Nigeria (BE) fatal<br>http://promedmail.org/post/2=
0240106.8714080=0D<br>2023=0D<br>----=0D<br>Lassa fever - West Africa (14):=
 Nigeria (BE)<br>http://promedmail.org/post/20231231.8713999=0D<br>Lassa fe=
ver - West Africa (13): Nigeria<br>http://promedmail.org/post/20231227.8713=
928=0D<br>Lassa fever - West Africa (12): Nigeria<br>http://promedmail.org/=
post/20231011.8712574=0D<br>Lassa fever - West Africa (08): Nigeria<br>http=
://promedmail.org/post/20230408.8709407=0D<br>Lassa fever - West Africa (07=
): Nigeria<br>http://promedmail.org/post/20230308.8708805=0D<br>Lassa fever=
 - West Africa (03): Nigeria<br>http://promedmail.org/post/20230213.8708341=0D=
<br>Lassa fever - West Africa (02): Nigeria<br>http://promedmail.org/post/2=
0230124.8707942=0D<br>Lassa fever - West Africa: Nigeria, 2022<br>http://pr=
omedmail.org/post/20230111.8707735]<br>....................................=
.............aa/may/ya/tw/jh<br></body>
</html><!DOCTYPE HTML>
<html>
<head>
<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3DUTF-8" />
</head>
<body>*##########################################################*<br>*****=
*******************************************************<br>ProMED makes eve=
ry effort to verify the reports that are posted, but the accuracy<br>and co=
mpleteness of the information, and of any statements or opinions based<br>t=
hereon, are not guaranteed. The reader assumes all risks in using informati=
on<br>posted or archived by ProMED. ISID and its associated service provide=
rs shall not<br>be held responsible for errors or omissions or held liable =
for any damages incurred<br>as a result of use or reliance upon posted or a=
rchived material.<br>******************************************************=
******<br>Donate to ProMED. Details available at: https://isid.networkforgo=
od.com/projects/79924-invest-in-the-mission.<br>***************************=
*********************************<br>Visit ProMED's website at https://www.=
promedmail.org/.<br>Submit all items for posting via the ProMED website at =
https://promedmail.org/submitinfo/.<br>If you have any questions or need su=
pport, please contact us via the ProMED website at  https://promedmail.org/=
support/.<br>You may subscribe/unsubscribe at  https://isid.org/promedmail-=
subscribe/.<br><div><a href=3D"https://u19268662.ct.sendgrid.net/asm/?user_=
id=3D19268662&amp;data=3DB60eYZtS9W6UIF-Dni9pGXN7hExwAH7GiSEiYlmiDh9oMDAwdT=
AwMJvVvijU-KxiToeug_yXhKXJmGJX47P0_naIkMj0HrNzZWPa1hFC5KK8K3GWPYCk3XptNvAgL=
ESLlakTNpwj-gwA759OSxsN0ZuA6iCxFLMfKrJrw7SccAd0yS5yrofhXjbdExeKv2siyy90BIed=
uugG9R7LhaWyBYg5wVbnDSQxfcaM1XRvwPM4IWhDRuBkJVd81AAfbK4j-W5BAs7oZzwyuCGH2Cp=
FZL7R7SUeiPJwS8xc81r_7cEYKEtkNuyw-xpyJJV-LYP14XSl4zFvNXczy8f1jneulVXlrYuPA8=
YYBuWDlnewrqPBVkqwS6RmEaJUtmpZGmPZygdFxrVZJgglhdDWfepUeOT-f1AnyTs2MA7_2TabZ=
EiPGxR8Ig0g_NPFvckDqdi7L-lY0mc7yhhHhQ3cYSqB890GSI2Y2yyaksA_55D6yhS5ypwvLd4K=
ANj7ds-2lESWNBpvySZTqam7I25BHb0-K3E-o-tiB-zzeXiqAP-zC5-M3Iyx4zxqp7WqgggbewA=
dA09U3__OaV1at_2ydTHpCXH_pygwUaRNhuV_2S9aGtf3XJkmbs-GhnjQFPhvxafddaHgGVdToj=
9Vo7-CFF5ZnSEIBNUX0Vr2IOCvtgjp0iOl2BuZNYFOH0ax_ioXmUlOyDmDJKtzL5x1FTEmHA8G1=
pNpReV3p9khqTGCMs91Rs33Z7akZN78S6RRaZ9ak8qus4uiwrKEreU4MgsLhcb845kMGTKzOXXs=
Ba1nnM3Ikzs-EKt2cU5jQqLM91BpPwRmu4gY8l9deOxgoU_Uj1HBBfgDoRmyaBB6Flba8Yl25pi=
SVKTtl72dvpmIMMurLHsvUJg_fyWiL6BFQVqO7OFoxSs-No3oi1rQjBuBL3-lMG37bwOm-fTeFk=
_uS0hjt9wNgqBWGf2LVQgd2vPuMe6X7wGpwTfGROBXXou-THcK4XBPonH5jV1Irw0GYzoXqH7oa=
1xzs45UNsEbu2_S1WwU2LYpXwzWNGXw6d624tjXL-sMaP_M8m_iDbW-Mha5BQ-MgJq5-FuWgvr8=
wafFsUz9CbXjIgy3HVCvYJmOKUmu3PmHt_nLQM_HbzuCw84VOLK01cAu382YwxgX2rBmc_gg-d9=
6MA1nHX5ARhsxHpQ0GcSpEmXRW5A4t0FWx4SMJ-CsseY2zbWgQZarm_aMikMZTOV5zqjws74e" =
target=3D"_blank" class=3D"Unsubscribe--unsubscribePreferences" style=3D"fo=
nt-family:sans-serif;text-decoration:none;">Unsubscribe Preferences</a></di=
v><br>############################################################<br>#####=
#######################################################<br><br><img src=3D"=
https://u19268662.ct.sendgrid.net/ss/o/LbtalBvHhFtzyiegKfBhew/430/Ngr20MNiS=
A2bTgypXA8XQA/ho.gif" alt=3D"" width=3D"1" height=3D"1" border=3D"0" style=
=3D"height:1px !important;width:1px !important;border-width:0 !important;ma=
rgin-top:0 !important;margin-bottom:0 !important;margin-right:0 !important;=
margin-left:0 !important;padding-top:0 !important;padding-bottom:0 !importa=
nt;padding-right:0 !important;padding-left:0 !important;"/></body>
</html>
--bb19a8ce0bf4d619f3ed13044c590a3c627cf12d6dde3a63b18fde0a7a3a--
